1163720-74-8

Basic information

• Product Name: tert-butyl (2-fluoro-4-((3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yl)oxy)phenyl)carbamate
• Synonyms: tert-butyl (2-fluoro-4-((3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yl)oxy)phenyl)carbamate
• CAS NO: 1163720-74-8
• Molecular Weight: 372.356
• Mol File: 1163720-74-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: tert-butyl (2-fluoro-4-((3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yl)oxy)phenyl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl (2-fluoro-4-((3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yl)oxy)phenyl)carbamate(1163720-74-8)
• EPA Substance Registry System: tert-butyl (2-fluoro-4-((3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yl)oxy)phenyl)carbamate(1163720-74-8)

Safety Data

• Hazardous Substances Data: 1163720-74-8(Hazardous Substances Data)

Upstream product

• 399-95-1 4-amino-3-fluorophenol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 6980-08-1 4-chloro-3-nitro-2-pyridinamine 
• 911297-02-4 N-(2-fluoro-4-hydroxyphenyl)carbamic acid tert-butyl ester 
• 1163720-60-2 4-(4-N-(tert-butoxycarbonyl)amino-3-fluorophenoxy)-3-nitro-2-aminopyridine 
• 1163720-66-8 4-(4-N-(tert-butoxycarbonyl)amino-3-fluorophenoxy)-2,3-diaminopyridine 
• 298-12-4 Glyoxilic acid 
• 924-44-7 glyoxylic acid ethyl ester 

Downstream Products

• 1163720-94-2 tert-butyl 4-(3-chloropyrido[2,3-b]pyrazin-8-yloxy)-2-fluorophenylcarbamate 
• 1163721-04-7 8-(4-amino-3-fluorophenoxy)pyrido[2,3-b]pyrazin-3(4H)-one 

Relevant articles and documents

POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES

The current invention provides urea derivatives, in particular compounds having the core structure heteroaryl-NH-CO-NH-aryl-O- heteroaryl, for use in treating, ameliorating, delaying, curing and/ or preventing a disease or condition associated with muscle cells and/or satellite cells, such as Duchenne muscular dystrophy, Becker muscular dystrophy, cachexia or sarcopenia.

Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors

Mutated BRAF serine/threonine kinase is implicated in several types of cancer, with particularly high frequency in melanoma and colorectal carcinoma. We recently reported on the development of BRAF inhibitors based on a tripartite A?B?C system featuring an imidazo[4,5]pyridin-2-one group hinge binder. Here we present the design, synthesis, and optimization of a new series of inhibitors with a different A?B?C system that has been modified by the introduction of a range of novel hinge binders (A ring). The optimization of the hinge binding moiety has enabled the development of compounds with low nanomolar potencies in both BRAF inhibition and cellular assays. These compounds display optimal pharmacokinetic properties that warrant further in vivo investigations.